PD-L1 × HYAL AbEn

PD-L1 × HYAL AbEn is an experimental antibody-enzyme fusion (AbEn) designed to modulate the tumor microenvironment (TME) by combining immune checkpoint inhibition with stromal remodeling. Developed by Tavotek Biotherapeutics using their proprietary conditional Fc-mediated antibody-enzyme (cFAE) technology, the molecule consists of a monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1) fused to the enzyme hyaluronidase (specifically the PH20 variant). The antibody component directs the fusion protein to PD-L1-expressing tumor cells, where the hyaluronidase enzymatic activity degrades hyaluronic acid (HA). HA accumulation in the TME creates a physical barrier and high interstitial fluid pressure that hinders the infiltration of cytotoxic T lymphocytes and the delivery of therapeutic agents. By depleting HA, PD-L1 × HYAL AbEn reduces tumor stiffness, promotes T-cell infiltration, and enhances the efficacy of both immune checkpoint blockade and chemotherapy. Preclinical studies in gastrointestinal and colorectal cancer models have demonstrated significant tumor growth inhibition and improved therapeutic responses compared to non-targeted hyaluronidase treatments.

Other names

PD-L1-targeted hyaluronidasePD-L-1-targeted hyaluronidasePD-L 1-targeted hyaluronidasePD-L1 x HYAL antibody-enzyme conjugatePD-L-1 x HYAL antibody-enzyme conjugatePD-L 1 x HYAL antibody-enzyme conjugate